Tobramycin Daptomycin

The US manufacturers briefly mention small studies in which daptomycin was given with aztreonam or tobramycin without any significant change in the pharmacokinetics of either drug. They also mention a study in which probenecid did not alter the pharmacokinetics of daptomycin. 

The polymyxin program did not proceed into the clinic but translatability was still addressed using samples from patients treated with a variety of standard of care antibiotics (piperacilhn/tazobactam, vancomycin, penicillin V, tobramycin, gentamicin, ampicillin, cefuroxime, clindomycin, clarithromycin, cefepime, daptomycin IV, bumetanide, vibramycin, and cyclophosphamide) compared to samples from healthy volunteers. This sample set was analyzed for sCr, BUN, urinary total protein, and urinary microalbumin as well as the emerging biomarkers urinary KIM-1, urinary NGAL, and urinary NAG. Much like the large animal studies with polymyxin B, the response for the antibiotic-treated cohort produced increases in all urinary- and serum-based... 

Wood CA, Finkbeiner HC, Ktdilhef SJ, Kohnen PW, Gilbert DN. Influence of daptomycin on staphylococcal abscesses and experimental tobramycin ncffluotoxicity. Antimicrob Agent Chemother 1989 33 1280-1285. 

Beauchamp D, Pellerin M, Gourde P. Petti ew M, Bergeron MG. Effects of daptomycin and vancomycin on tobramycin nephrotoxicity in rats. Antimicrob Agent Chemother 1990 34 139-147. 

Beauchamp D, Gourde P, Simaid M. Bergeron MG. Subcellular distribution of daptomycin given alone or with tobramycin in renal proximal tubular cells. Antimicrob Agent Chemother 1994 38 189-194. 

---